James A Underberg
Overview
Explore the profile of James A Underberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
685
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cuchel M, Lee P, Hudgins L, Duell P, Ahmad Z, Baum S, et al.
J Am Heart Assoc
. 2023 Apr;
12(9):e029175.
PMID: 37119068
Background Homozygous familial hypercholesterolemia (HoFH) is a rare, treatment-resistant disorder characterized by early-onset atherosclerotic and aortic valvular cardiovascular disease if left untreated. Contemporary information on HoFH in the United States...
2.
Willard K, Soffer D, Underberg J, Guyton J
J Clin Lipidol
. 2023 Mar;
17(2):199-207.
PMID: 36965957
The prevalence of lipid-related risk for atherosclerotic cardiovascular disease surpasses half the population as individuals age, and thus generalists and primary care providers manage by far the bulk of treatment...
3.
Maki K, Bays H, Ballantyne C, Underberg J, Kastelein J, Johnson J, et al.
J Am Heart Assoc
. 2022 Mar;
11(6):e024176.
PMID: 35232215
Background MAT9001 is an omega-3 free fatty acid (FFA) formulation containing mainly eicosapentaenoic acid (EPA) and docosapentaenoic acid (DPA). Compared with icosapent ethyl (EPA-ethyl esters [EE]), EPA+DPA-FFA previously showed enhanced...
4.
Maher L, Tokgozoglu S, Sanchez E, Underberg J, Guyton J
J Clin Lipidol
. 2021 Jun;
15(3):387-393.
PMID: 34144765
Lipoprotein(a) operates in causal pathways to promote atherosclerosis, arterial thrombosis, and aortic stenosis. It has been associated with rare cases of nonatherosclerotic arterial thrombotic stroke at any age. Inherited variation...
5.
Underberg J, Cannon C, Larrey D, Makris L, Blom D, Phillips H
J Clin Lipidol
. 2020 Oct;
14(6):807-817.
PMID: 33023859
Background: Lomitapide is a lipid-lowering agent indicated as adjunct therapy for homozygous familial hypercholesterolemia (HoFH) in adults. Objective: The Lomitapide Observational Worldwide Evaluation Registry is an international, observational registry assessing...
6.
Brown E, Sturm A, Cuchel M, Braun L, Duell P, Underberg J, et al.
J Clin Lipidol
. 2020 Jun;
14(4):398-413.
PMID: 32507592
The genetic basis for more than 2 dozen monogenic dyslipidemias has largely been defined. Genetic technologies, such as DNA sequencing, can detect both rare and common DNA variants underlying dyslipidemias,...
7.
Duell P, Gidding S, Andersen R, Knickelbine T, Anderson L, Gianos E, et al.
Atherosclerosis
. 2019 Sep;
289:85-93.
PMID: 31487564
Background And Aims: There are limited data from the US on outcomes of patients in specialty care for familial hypercholesterolemia (FH). Methods: CASCADE FH Registry data were analyzed to assess...
8.
Garshick M, Vaidean G, Vani A, Underberg J, Newman J, Berger J, et al.
Cardiology
. 2019 May;
142(2):83-90.
PMID: 31079098
Background: While progress in the prevention of cardiovascular disease (CVD) has been noted over the past several decades, there are still those who develop CVD earlier in life than others....
9.
Vani A, Underberg J
Clin Pharmacol Ther
. 2018 Jun;
104(2):290-296.
PMID: 29882959
Atherosclerotic cardiovascular disease (ASCVD) is the number one cause of morbidity and mortality worldwide. Low-density lipoprotein cholesterol (LDL-C) has been implicated as one of the major risk factors causing ASCVD...
10.
Amrock S, Duell P, Knickelbine T, Martin S, OBrien E, Watson K, et al.
Atherosclerosis
. 2017 Oct;
267:19-26.
PMID: 29080546
Background And Aims: Most familial hypercholesterolemia (FH) patients remain undertreated, and it is unclear what role health disparities may play for FH patients in the US. We sought to describe...